Corrigendum to “Synthesis and structure–activity relationships of N-{1-[(6-fluoro-2-naphthyl)methyl]piperidin-4-yl}benzamide derivatives as novel CCR3 antagonists” [Bioorg. Med. Chem. 16 (2008) 144–156]
Ippei Sato(Astellas Pharma (Japan)), Shin‐ichi Tsukamoto(Astellas Pharma (Japan)), Yosuke Iura(Toray (United States)), Hirokazu Kubota(Astellas Pharma (Japan)), Koichiro Morihira(Astellas Pharma (Japan)), Toshiya Takahashi(Tohoku University), Takayuki Imaoka(Toray Industries, Inc. (Japan)), Keiko Suzuki(Astellas Pharma (Japan)), Tatsuaki Morokata(Astellas Pharma (Japan)), Makoto Takeuchi(Kirin (Japan)), Noritaka Hamada(Astellas Pharma (Japan)), Hiroshi Inami(Astellas Pharma (Japan)), A. Nitta(Toray (United States)), Mitsuaki Ohta(Tokyo University of Agriculture)
Cited by 3
Related Papers
Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double‐Blind, Randomized, Parallel‐Group Trial
|Arthritis & Rheumatology|2016|119
Psoriasis and Antimicrobial Peptides
|International Journal of Molecular Sciences|2020|114
An In Vitro Test to Screen Skin Sensitizers Using a Stable THP-1–Derived IL-8 Reporter Cell Line, THP-G8
|Toxicological Sciences|2011|93
Cathelicidin promotes inflammation by enabling binding of self-RNA to cell surface scavenger receptors
|Scientific Reports|2018|84